References
- Storb R, Blume KG, O'Donnell MR et al. Cyclophosphamide and antithymocyte globulin to condition patients with aplastic anemia for allogeneic marrow transplantations: the experience in four centers. Biol Blood Marrow Transplant 2001; 7: 39–44.
- Champlin RE, Perez WS, Passweg JR et al. Bone marrow transplantation for severe aplastic anemia: a randomized con-trolled study of conditioning regimens. Blood 2007; 109: 4582–4585.
- Zheng Y, Liu Y, Chu Y. Immunosuppressive therapy for acquiredsevere aplastic anemia (SAA): a prospective comparison of four different regimens. Exp Hematol 2006; 34: 826–831.
- Okuda S, Terasako K, Oshima K et al. Fludarabine, cyclopho-sphamide, anti-thymocyteglobulin, and low-dose total body irradiation conditioning enables 1-HLA-locus-mismatched hema-topoietic stem cell transplantation for very severe aplastic anemia without affecting ovarian function. Am J Hematol 2009; 84: 167–169.
- Deeg HJ, Amylon ID, Harris RE et al. Marrow transplants fromunrelated donors for patients with aplastic anemia: minimum effective dose of total body irradiation. Biol Blood Marrow Transplant 2001; 7: 208–215.
- Oshima K, Kanda Y, Nakasone H et al. Decreased incidence of acute graft-versus-host disease by continuous infusion of cyclos-porine with a higher target blood level. Am J Hematol 2008; 83: 226–232.
- Kanda Y, Mineishi S, Saito T et al. Long-term low-dose acycloviragainst varicella-zoster virus reactivation after allogeneic hemato-poietic stem cell transplantation. Bone Marrow Transplant 2001; 28: 689–692.
- Asano-Mori Y, Kanda Y, Oshima K et al. Long-term ultra-low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation. Am J Hematol 2008; 83: 472–476.
- Asano-Mori Y, Kanda Y, Oshima K et al. Clinical features of latecytomegalovirus infection after hematopoietic stem cell transplan-tation. Int J Hematol 2008; 87: 310–318.
- Kanda Y, Mineishi S, Saito T et al. Response-oriented preemptive therapy against cytomegalovirus disease with low-dose ganciclovir: a prospective evaluation. Transplantation 2002; 73: 568–572.
- Thiede C, Florek M, Bornhauser M et al. Rapid quantification of mixed chimerism using multiplex amplification of short tandem repeat markers and fluorescence detection. Bone Marrow Transplant 1999; 23: 1055–1060.
- Basara N, Baurmann H, Kolbe K et al. Antithymocyte globulin for the prevention of graft-versus-host disease after unrelated hema-topoietic stem cell transplantation for acute myeloid leukemia: results from the multicenter German cooperative study group. Bone Marrow Transplant 2005; 35: 1011–1018.
- Gaber AO, First MR, Tesi RJ et al. Results of the double-blind, randomized, multicenter, phase III clinical trial of Thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplantation. Transplantation 1998; 66: 29–37.
- Brennan DC, Flavin K, Lowell JA et al. A randomized, double-blinded comparison of Thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients. Transplantation 1999; 67: 1011–1018.
- Norrby J, Olausson M. A randomized clinical trial using ATG Fresenius or ATG Merieux as induction therapy in kidney transplantation. Transplant Proc 1997; 29: 3135–3136.
- Ourahma S, Talon D, Barrou B et al. A prospective study on efficacy and tolerance of antithymocyte globulin Fresenius versus thymoglobuline Merieux after renal transplantation. Transplant Proc 1997; 29: 2427.
- Ducloux D, Kazory A, Challier B et al. Long-term toxicity of antithymocyte globulin induction may vary with choice of agent: a single-center retrospective study. Transplantation 2004; 77: 1029–1033.
- Kanda Y, Mineishi S, Nakai K et al. Frequent detection of rising cytomegalovirus antigenemia after allogeneic stem cell transplan-tation following a regimen containing antithymocyte globulin. Blood 2001; 97: 3676–3677.
- Nichols WG, Corey L, Gooley T et al. Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomes. Blood 2001; 97: 867–874.
- Asano-Mori Y, Oshima K, Sakata-Yanagimoto M et al. High-grade cytomegalovirus antigenemia after hematopoietic stem cell transplantation. Bone Marrow Transplant 2005; 36: 813–819.
- Kim HJ, Min WS, Cho BS et al. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplanta-tion for acute myelogenous leukemia. Biol Blood Marrow Transplant 2009; 15: 704–717.